Category Archives: Immunology

Growing Demand for Personalized Medicine Will Drives the Humanized Mouse and Rat Model Market – Press Release – Digital Journal

The Humanized Mouse Model Market is projected to reach USD 128.9 Million, at a CAGR of 9.9% during the forecast period.

This press release was orginally distributed by SBWire

Northrook, IL -- (SBWIRE) -- 02/24/2020 -- The key factors propelling the growth of the market are the increasing number of research activities involving humanized models, growing demand for personalized medicine, an increasing number of R&D activities in pharmaceutical and biotechnology companies, and continuous support in the form of investments and grants from the government and private sectors. The objective of the report is to define, describe, and forecast the humanized mouse model market size based on type, application, end-user, and region.

According to the new market research report "Humanized Mouse and Rat Model Market by Type (Genetic, Cell-Based (CD34, PBMC, BLT)), Application (Neuroscience, Hematopoiesis, Oncology, Immunology & Infectious Diseases) & End User (Pharmaceutical & Biotechnology Companies, CRO)) - Global Forecast", published by MarketsandMarkets.

The Humanized Rat Model market is expected to reach USD 8.9 Million by 2022 from USD 5.9 Million in 2017, at a CAGR of 8.4% during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131763955

Market Segmentation in Detailed:

Based on type, the market is segmented into a humanized mouse and humanized rat. The Humanized mouse model market is further segmented into a cell-based and genetic-based humanized mouse model. The genetic humanized mouse models segment accounted for the largest share of the market. The large share of this segment can be attributed to the wide use of genetic humanized mouse models in the analysis of compounds, biological efficacy and safety testing, the study of drug metabolism and disposition, and investigation of immune system development and function.

Based on application, the market is segmented into oncology, immunology and infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications. The oncology segment is expected to witness the highest growth, owing to the rising number of cancer research activities and increasing innovation to develop humanized mouse models tailored to meet the specific needs of cancer research.

Based on end-user, the market is segmented into pharmaceutical & biotechnology companies, contract research organizations (CROs), and academic & research institutions. The CROs segment is estimated to register the highest CAGR during the forecast period due to the growth in the number of pharmaceutical companies outsourcing their preclinical studies to CROs.

Worldwide Geographical Analysis:

The North American region is leading the humanized mouse models market is expected to account for the largest share of the market in 2017. Growth in this regional segment can primarily be attributed to growing biomedical research, preclinical activities by CROs and pharmaceutical R&D, continued and responsible use of animals ensured by animal care organizations, increasing monoclonal antibody production in the US along with growing stem cell research, and government support for the development of protein drugs in Canada

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=131763955

Major Key Players Operating in Industry:

The Jackson Laboratory (US), Taconic Biosciences, Inc. (US), Horizon Discovery Group plc (UK), genOway, S.A. (France), Charles River Laboratories (US), Harbour Antibodies BV (China), Hera BioLabs (US), Vitalstar Biotechnology Co., Ltd. (China), inGenious Targeting Laboratory (US), AXENIS S.A.S (France), Crown Bioscience, Inc. (US), Transgenic, Inc. (Japan), and Champions Oncology, Inc. (US). The major players in the humanized rat models market include Horizon Discovery Group plc (UK), Hera BioLabs (US), and Yecuris Corporation (US).

For more information on this press release visit: http://www.sbwire.com/press-releases/release-1278836.htm

Read the original:
Growing Demand for Personalized Medicine Will Drives the Humanized Mouse and Rat Model Market - Press Release - Digital Journal

Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2020 AAAAI Annual Meeting – GlobeNewswire

REDWOOD CITY, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the Company) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced that the Company will present clinical and preclinical results in a number of diseases where mast cells and/or eosinophils have been shown to play a role in disease pathology. The presentations will take place at the 2020 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting being held in Philadelphia, Pa. from March 13 to 16, 2020.

Oral Presentations:

Featured Poster Presentations:

Poster Presentations:

Following the presentations, the posters will be available on the Allakos website.

About Allakos Allakosis a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Companys lead antibody, antolimab (AK002), targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Antolimab (AK002) has been shown to inhibit mast cells and deplete eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. Antolimab (AK002) has been tested in five clinical studies. In these studies, antolimab (AK002) eliminated blood eosinophils and improved disease symptoms in patients with eosinophilic gastritis and/or eosinophilic gastroenteritis, eosinophilic esophagitis, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. For more information, please visit the Company's websiteat http://www.allakos.com

Source: Allakos Inc.

See the original post here:
Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2020 AAAAI Annual Meeting - GlobeNewswire

Infectious Immunology Market Overview and Forecast up to 2019 2027 – Jewish Life News

According to a report published by TMR market, the Infectious Immunology economy is expected to witness a CAGR growth of XX% within the forecast period (2019-2029) and reach at a value of ~US$ at the ending of 2029. The macro-economic and micro elements which are predicted to influence the trajectory of this market are studied in the presented market study.

Light on the raw material throws Suppliers, vendors, manufacturers, and market consumers at the markets value chain. Furthermore, the political and economic scenarios of regions and its effect on the Infectious Immunology market are discussed within the accounts.

Critical Insights enclosed from this report:

Request Sample Report @ https://www.transparencymarketresearch.co/sample/sample.php?flag=B&rep_id=2929

Competitive Outlook

Light onto the throws Business prospects of prominent players operating from the Infectious Immunology sector. The item pricing plans, marketing stations that were preferred , product portfolio of most players, and promote presence of each and every company is contained in the report. The dominant players covered in the report include Business, Business two, Business 3, and Company 4.

Regional Assessment

The presented market study sheds light on the Marketplace Scenario in various markets. Furthermore, the governmental and regulatory policies to the prospects of the Infectious Immunology market in each regions effect is analyzed in the report.

market segments, major geographies, and current market trends. Geographies analyzed under this research report include

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porters five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Excerpt from:
Infectious Immunology Market Overview and Forecast up to 2019 2027 - Jewish Life News

Harvard Scientists to Collaborate with Chinese Researchers to Improve Diagnostics and Develop Novel Coronavirus Therapies | News – Harvard Crimson

A team of Harvard scientists will collaborate with a Chinese research institute in a five-year effort to study the novel coronavirus, which has infected more than 78,000 people worldwide, according to a University press release Monday.

Co-led by Harvard Medical School Dean George Q. Daley and Zhong Nanshan the head of an expert team within Chinas National Health Commission that is investigating the outbreak the partnership will focus on creating more accurate diagnostic tests and designing vaccines, antiviral therapies, and treatments. Members of the group have held two video chats since its formation to begin the partnership, according to University spokesperson Jason A. Newton.

According to the press release, Daley said that the Medical School is uniquely positioned to bring together experts in virology, infectious diseases, structural biology, pathology, vaccine development, epidemiology, and public health for the project.

Harnessing our science to tackle global health challenges is at the very heart of our mission as an institution dedicated to improving human health and well-being worldwide, he said in the release.

The two research partners will share $115 million in funding from China Evergrande Group, a real estate giant and Fortune Global 500 company.

Zhong gained international recognition for his work combatting the 2003 Severe Acute Respiratory Syndrome outbreak. He was also the first scientist to publicly confirm human-to-human transmissibility during 2019s n-Cov epidemic.

We are extremely encouraged by the generous gesture from Evergrande to coordinate and support the collaboration and by the overwhelmingly positive response from our Harvard colleagues, Zhong said in the press release.

We look forward to leveraging each of our respective strengths to address the immediate and longer-term challenges and a fruitful collaboration to advance the global well-being of all people, he added.

Hui Ka Yan, who chairs China Evergrande Group, said in the press release that the company is honored to work to stop the outbreak. The groups CEO, Xia Haijun, visited University President Lawrence S. Bacow in Cambridge last Wednesday, according to a statement from the company.

Evergrande is honored to have the opportunity to contribute to the fight against this global public health threat, Hui Ka Yan said in Harvards press release. We thank all the scientists who responded so swiftly and enthusiastically from the Harvard community and are deeply moved by Harvard and Dr. Zhongs teams dedication and commitment to this humanitarian cause. We have the utmost confidence in this global collaborative team to reach impactful discoveries against the outbreak soon.

Bacow said in the release that the collaborators are confident that their work will contribute valuable discoveries to broader global efforts to combat coronavirus.

We are grateful for Evergrandes leadership and generosity in facilitating this collaboration and for all the scientists and clinicians rising to the call of action in combating this emerging threat to global well-being, he said.

Harvard affiliates participating in the effort include Daley; Medical School Dean for Research Operations and Global Programs David E. Golan; Immunology department chair Arlene H. Sharpe; Medicine professor Bruce D. Walker; Harvard School of Public Health Center for Communicable Disease Dynamics director Marc Lipsitch; and Lindsey R. Baden, the director of clinical research in Brigham and Womens Hospitals Division of Infectious Diseases.

Staff writer Michelle G. Kurilla can be reached at michelle.kurilla@thecrimson.com. Follow her on Twitter @MichelleKurilla.

Staff writer Ruoqi Zhang can be reached at ruoqi.zhang@thecrimson.com. Follow him on Twitter @RuoqiZhang3.

See the rest here:
Harvard Scientists to Collaborate with Chinese Researchers to Improve Diagnostics and Develop Novel Coronavirus Therapies | News - Harvard Crimson

Basic Immunology | The IBD Immunologist

The immune system, defined in the simplest terms, is the system in our bodies that defends us against infectious disease. However, our immune systems are far more complex. Not only does it defend us against pathogens, it is also responsible for protecting us against cancer, initiating allergy symptoms, and determining the state of our general health.

The Immune system itself is like a miniature world in our bodies, and it is populated with various immune cells that are supported by the cells making up the tissues and organs of the body. Each type of immune cell has its own specialized function. Some are good at fighting infectious bodies hand to hand like soldiers, while others are specialized at scouting, intelligence and recruitingother cell types during battle. During an immune response, the cells of the surrounding tissues also play their roles and, much like civilians in war, they fight, warn others, or die as a result of the battles.

I will do my best to introduce you to this exciting world in simple terms.

To put it quite simply, the Immune System is designed to protect you. Immunologist refer to the body often as self. This includes all the products of the body ranging from your tissues to the smallest secreted molecules. Life forms and molecules that interact with your body are considered non-self. The non-self life forms are parasites, bacteria and viruses as well as friendly intestinal bacteria. Common non-self molecules that we often encounter are food, pollen and chemical substances from our environments (like drugs, cleaning products and hygienic products)1.

Cells of the immune system are born from hematopoietic stem cells found deep in the bone marrow. Hematopoietic stem cells are immortal, capable of generating daughter cells, called progenitors that will later give rise to different type of immune cells. There are two main types of progenitors created, the myeloid progenitors and the lymphoid progenitors2.

Cells of Myeloid Progenitors

For immunologists, the mammalian body is divided into three main regions: the primary lymphoid areas, the secondary lymphoid areas and the periphery.

The primary lymphoid areas include the bone marrow and the thymus. The bone marrow, as we mentioned, is the site of immune cell generation2. The thymus, on the other hand, is the location of T cell development4. Lymphoid progenitor populations travel there from the bone marrow and produce a population of immature thymocytes. It is these thymocytes that give rise to the varied T cell populations.

The secondary lymphoid areas include the adenoids, tonsils, spleen, lymph nodes and lymphoid follicles found in the gastrointestinal system and the mucosa (areas adjacent to a mucus membrane). These areas house lymphocytes and support the development of an adaptive immune responses5-7.

The periphery includes all regions that are not included in the primary and secondary lymphoid areas. This includes areas like the skin, brain, joints, muscles and gastrointestinal/mucosal areas surrounding lymphoid follicles.

In order for an immune response to be initiated, there must be some kind of danger. This is a fairly simple idea, but it leads to the question: How is danger defined by the immune system? This question is actually one of the most exciting topics of immunology today. Simply put, danger is sensed by the immune system through two main avenues: the recognition of a pathogen-associated molecular pattern (PAMP)8 or through the release of cell molecules associated with trauma which are called danger-associated molecular patterns (DAMPs) or alarmins9. Examples of PAMPs would be cell wall lipoproteins of bacteria and an example of DAMPs would be ATP (adenosine triphosphate), a nucleotide used as an energy source in cells10.

PAMPs and DAMPs are recognized by the cells of the immune system and non-immune cells, through receptors located at the cell surface or internally8,9. PAMPs are also recognized by several non-cellular systems as well11,12. This recognition initiates the very first processes of an immune response called the innate immune response.

Immune cells, non-immune cells and non-cellular systems all participate in initiating an innate immune response. Why is it called innate? Its innate because it depends on intrinsic systems that are built into your body to recognize danger and there is no learning or adaptation involved.

In order to detect PAMPs or DAMPs, cells need tools to recognize them. These tools are protein receptors that can be found on the cell surface as well as internally. In general, they are called pattern recognition receptors or PRRs. These receptors come in families consisting of multiple members. Receptors that recognize PAMPs include the Toll-like receptors (TLRs), the C-type lectin receptors (CLRs), the NOD-like receptors (NLRs), RIG-I-like receptors (RLRs)8 and invariant T cell receptors13,14.

DAMP receptors are not so clear-cut. TLRs have been implicated15 as well as the receptor for advanced glycation endproducts (RAGE)15. Also the purinergic receptors that recognize ATP would also fall into this category10.

These receptors are found on most cells of the body. They recognize a variety patterns associated with a number of pathogens including virus-associated nucleic acids; bacterial-associated cell wall components, protein, ribosomal RNA and DNA; and protozoan-associated proteins8. The majority is found extracellularly, but a number are also found intracellularly. When stimulated they activate the transcription factor NFB, which is essential for activating a cells immune functions and set off a signal cascade via MAP kinase (a phosphorylating enzyme)8.

These receptors are specialized in recognizing carbohydrate structures, such as the sugar mannose, which is a common component of fungal cell walls16. Thus, these receptors are found on the cell surface. Though much of the literature involves their expression on immune cells, reports of CLR variants on non-immune cells can also be found17. On the phagocytic cells, it is known that they can participate in endocytosis, the engulfment of particles or pathogens and respiratory burst16. Some also appear to initiate signal cascades similar to TLRs leading to NFB and MAP kinase activation, but it also appears that they can work in concert with TLRs, enhancing or inhibiting their function16.

These receptors are found in the cytoplasm of cells. Traces of their expression is found in most organs of the body18 and it is probably safe to say that most immune cells express at least some members of the NLR family. These receptors are designed to detect intracellular bacteria and, possibly, endogenous stress molecules and allow the cell to produce one of the most potent inflammatory mediators, Interleukin (IL)-119.

Like NLRs, RLRs are also found in the cytoplasm of a cell. Instead of detecting bacterial products, these receptors help detect viral infection20. They do this by binding to RNA produced during viral replication. Working together with nucleic-acid detecting TLRs, they lead to NFB, MAP kinase activation and activation of Interferon regulatory factor (IRF) transcription factors20. The IRF transcription factors are necessary to produce cytokines specialized for the control of viral infections. Cytokines are small, secreted proteins used as messengers between cells, which alert surrounding immune cells about danger.

Areas of the body that come in contact with the outside world (skin, gastrointestinal and mucosal areas) are covered with an epithelial layer. Epithelial layers are composed mainly of cells called epithelial cells. These cells form an anatomical barrier and they have their own immune functions. When exposed to DAMPs or PAMPs, epithelial cells produce inflammatory cytokines 21. The cells of the epithelial layer are often the main cells involved in the first detection of pathogens and/or danger. The majority of cells in the body also have this capacity. Other cell types like muscle cells, adipocytes and fibroblasts are all outfitted with receptors to detect PAMPs and DAMPs8,22. Just like citizens of a city, they will alert the authorities if there are any problems.

Under epithelial layers are resident macrophages, neutrophils, dendritic cells, NK cells, mast cells and a number of T cell-related cells.

The name macrophage is derived from Greek, meaning large eaters. Their main function is to phagocytize (engulf) pathogens and particles. It does this by wrapping its plasma membrane around particles until they are enveloped and pinched off to form an endosome inside the cell. Once inside the cell, the endosome merges with a lysosome that contains enzymes and acids that can digest the contents. Macrophages also have the ability to generate a respiratory burst, which is a release of oxygen radicals that damage surrounding pathogens and cells. They also can alert and attract other immune cells through inflammatory cytokine release23.

Neutrophils are the main foot soldiers of the innate immune response and are certainly the most abundant. They also have a wide arsenal of tools to deal with invaders. Like macrophages, neutrophils can phagocytize particles, release a respiratory burst and produce inflammatory cytokines. Unlike macrophages, neutrophils have the internal caches of anti-microbial substances called granules24.

Dendritic cells are also phagocytic cells, but they have the special ability of initiating an adaptive immune response (will be discussed later). Unlike neutrophils and macrophages, Dendritic cells or DCs are not simple foot soldiers. Instead, they function more as spies and provide intelligence about invaders to T cells through a phenomenon called antigen presentation and through cytokine production25.

The NK stands for Natural Killer and the name implies their function. These cells, however, do not kill pathogens directly. Instead, these cells have the ability to recognize when other cells are harboring internal pathogens using special receptors and then kill them. Situations where this might occur is during viral and mycobacterial infections. These pathogens easily reside in host cells, finding ways to block lysosome fusion and their own destruction26.

Mast cells are the cells that are responsible for the classic signs of inflammation, which include redness, swelling and heat. Though well known for their association with allergy, they also can detect PAMPs and DAMPs through receptors and become immunologically active. Mast cells exert their functions mainly through cytokine and granule release. Unlike neutrophils, which release antimicrobial substances, mast cells release histamine and heparin. Histamine is well known for its vasodilator function and ability to allow fluid to leak between cells, causing redness and swelling. It also causes inflammatory itching by triggering neurons (unmyelinated C-fibers) responsible for the itch feeling. Heparin prevents blood coagulation27.

Most T cells are part of the adaptive immune response as they have adaptive T cell receptors (receptors that learn to recognize pathogens). NK T cells and T cells, however, use invariant T cell receptors (receptors that do not rearrange) or semi-invariant T cell receptors and participate in the innate immune response.

NK T cells are similar to the NK cells mentioned above. Not so much in function, but more in how they look. These cells share many of the same surface protein markers. NK T cells, however, do not kill compromised cells. Instead, they are quick cytokine producers. In doing so, they quickly notify all surrounding cells that there is problem when they recognize PAMPs presented to them via dendritic cells28.

The T cells are important for innate immune reactions and the adaptive immune response as they have invariant and variant T cell receptors. Their precise function remains unclear, but they can secrete cytokines and, like the NK T cells above, participate in alerting and strengthening local immune responses29.

Besides cells, there are also defenses in your body that are ready to react to pathogens as soon as they are encountered, much like booby traps. These systems rely on small proteins that are found within the bodily fluids.

The liver synthesizes the proteins of the complement system and they work in concert to aid in phagocytosis, bacteria lysing and immune cell attraction. One can visualize it as a self-assembling machine that starts to assemble as soon as the first proteins are bound and in place. The complement machine is known to be initiated by three different pathways: the classical pathway, the alternative pathway and the lectin pathway. The classical pathway is triggered when antibodies are bound to a pathogen. The alternative pathway is triggered when the victim is unable to block the cascade (normal cells can, while pathogens cannot). The lectin pathway uses free lectin proteins (lectins are proteins that bind sugars) to bind sugars associated with bacterial cell walls)11.

These proteins are also produced by the liver and especially during inflammation when pro-inflammatory cytokines are produced. Many are designed to coat pathogens and have chemotactic properties (have the ability to attract cells). Some inhibit microbial growth by sequestering iron from the environment. The lectins from the lectin pathway of complement activation are considered acute phase proteins30.

Often called defensins, these peptides function as natural antibiotics and our produced by cells that guard the external surfaces and internal surfaces such as the skin and the gastrointestinal system. In the skin, the main sources are keratinocytes, mast cells, neutrophils, sebocytes and eccine epithelial cells. In the intestines, one of the main producers are the Paneth cells of intestinal crypts31.

The adaptive immune response is what gives individuals long-term immunity to a pathogen after vaccination. Instead of relying on germ-line encoded receptors for the recognition of pathogens like the innate immune system, it depends on the development of receptors that can recognize any unique molecular characteristic of pathogens32. The molecules that can be recognized are called antigens. The classical definition of an antigen is any molecule that can provoke the development of antibodies. A better, and less-confusing, definition is a molecule that can be recognized by the adaptive immune system. The molecules are often protein peptides (small pieces of protein). But, they can also be sugars, lipids and other small molecules under the right circumstances. The main players of the adaptive immune response are the T cells (both T helper cells and cytotoxic T cells) and the B cells.

During the innate immune response, the first steps are taken to initiate an adaptive immune response. The main cells responsible for this step are the DCs that we described earlier25. As we mentioned before, DCs are a phagocytic cell type. This means that they have the ability to engulf pathogens/particles in endosomes and later fuse these vesicles to lysosomes for destruction. The process, however, does not stop here. Instead of just disposing of the pathogen/particle waste, the DC, instead, uses these parts to educate T helper cells about the pathogens. It does this by traveling from the location where it picked up its parcel to the local lymph node, where it finds T helper cells. Once there, it presents the pathogen-associated peptides on its surface using molecules called MHC class II molecules and provides information to T cells about how it should respond using surface molecules called co-stimulatory molecules and cytokines. Educating T helper cells is the first step towards initiating an adaptive immune response.

T helper cells or Th cells are crucial cells in the adaptive immune response and they are characterized by a surface protein called, CD4. They hold the key to initiating the functions of cytotoxic T cells33 and B cells34. Furthermore, they can also increase the efficacy of macrophages23.

Th cells interact with the MHC class II/peptide complexes presented by antigen presenting cells through its receptor, called the T cell receptor (TCR). If a T cell has never before seen antigen, it is called a nave T cell. In this situation, the T cell will need instruction from a professional antigen presenting cells, usually a DC, about how to perform its function. DCs do this through cell surface proteins call co-stimulatory molecules and through cytokine expression. This process is consists of three main signals. The first signal is the antigen recognition; the second signal is co-stimulation and the third cytokine exposure. This whole process is referred to as priming of the nave T cell. Once primed, the T cells begin to divide; a process that is referred to as expansion or proliferation35.

The most important set of co-stimulatory molecules is CD80 or CD86 on the DC and CD28 on the T cells. This second signal is necessary to tell the Th cell that there is a problem. If signal one is given without this second signal, the T cell will assume that the antigen is actually harmless and become non-responsive in a process called anergy36. Only a DC that has encountered a PAMP or another danger signal will express CD80 or CD86 on its surface reassuring the Th cell that there is, indeed, a problem.

Signal three is the secretion of cytokines of the DC. There are several cytokines important for Th cell eduction. They most important ones are IL-4, IL-12, IL-6, TGF and IL-10. Th cells will differentiate into different types of Th cells depending on which cytokines prevail. The main types of Th cells are T helper 1 (Th1) cells, T helper 2 (Th2) cells, T helper 17 (Th17) cells, and induced regulatory T cells (iTreg)35.

Each Th cell subtype has its own unique set of skills. One could almost see differentiation as an occupation. Just like an athlete will choose to develop her body and a scientist will choose to develop her mind. In humans, these choices are reflected at the level of gene transcription and protein expression. The athlete will stimulate muscle growth and the scientist develops the cerebral cortex of the brain. Its the same for Th cell differentiation. The four main subtypes of Th cells are listed. There are, however, rare forms that have been observed that are not listed and Th cells, much like humans, can fall into gray areas between the stereotypes.

The Th1 path is chosen when T cells are exposed to IL-12 during priming. Th1 cells are characterized by the production of the cytokine, interferon- (IFN) and the expression of the master transcription factor, T-bet. Th1 cells are experts at gearing the immune response towards to the control of internal pathogens like viruses and mycobacteria, which reside internally in macrophages. They perform this function by initiating cytotoxic T cell responses, helping macrophages to become more effective, by helping B cells to produce certain types of antibodies. These functions are executed, in part, through IFN exposure, however, some require cell-cell contact and will be explained in more detail later37.

Th2 cells are created during exposure to high amounts of IL-4. This leads to the expression of the Th2-associated master transcription factor, GATA3. Th2 cells are also characterized by the production of IL-4 (indeed, the same cytokine needed to create them). These cells are designed to skew the immune system towards a humoral immune response (antibody response) that can deal with parasite infection. Unfortunately, Th2 responses are also the ones associated with allergy development as well. Th2 cells do their work by effectively helping B cells and encouraging specific forms of antibodies. This is done through a combination of IL-4 exposure and cell-cell interactions37.

The Th17 subtype is the most recently described of the Th subtypes. It is most effective at controlling extracellular bacterial and fungi responses, like those found during intestinal food poisoning or during a yeast infection. Its creation is dictated by the cytokines IL-6 and TGF and this leads to the expression of the master transcription factor, RORt. Th17 cells produce the cytokine IL-17. IL-17 production is one of the main facilitators of their function and it encourages surrounding cells to increase neutrophil migration. Neutrophils are excellent phagocytic cells with many bacterial killing tools38.

To those just learning about the immune system, the existence of the following Th subtype may be confusing. iTreg are designed to counter the functions of other immune cells. Why? The reason is that immune responses are highly damaging to surrounding tissues and, without them, immune responses would spiral out of control.

That said; these cells are induced by DCs when they are exposed to high amounts of IL-10 or TGF. This causes the expression of the master transcription factor, Foxp3. In turn, iTreg produce IL-10 or TGF. IL-10 and TGF are what is called anti-inflammatory cytokines. They have the ability to limit the functions of immune cells. IL-10, for instance, lowers Th1 and Th17 responses and reduces macrophage efficacy. TGF encourages apoptosis (induced death of cells), prevents cell division and lowers phagocytosis39.

Th cells are not the only kind of T cell. Cytotoxic T cells (CTLs), characterized by the surface marker CD8, are not to be missed and are essential for the elimination of viral infections. The function of a CTL is found in its name. Cyto refers to cell and toxic means just how it sounds. These cells are cell toxic and kill other cells. In many ways, they are similar to the NK cells and NK T cells of the innate immune system. However, they do not use invariant receptors to recognize problems in other cells, but instead use an adaptive system.

CTLs, like Th cells, have a TCR. This means that they can detect unique peptides presented to them by other cells. In the case of Th cells, these are MHC class II molecules presented via DCs. In the case of CTLs, they are MHC class I molecules. During an infection, as we earlier mentioned, DCs will travel to the lymph node and present samples of the intruder to the T cells. This is also happens for CTLs. However, despite the presence of all the priming signals, priming will be suboptimal. CTLs need an additional signal, jokingly called the license to kill. This signal is given by a Th1 cell through the production of a cytokine called IL-2, which stimulates CTL expansion; and through an interaction between the Th1 cell and the DC via CD40 on the DC and CD40 ligand on the Th1 cell, which makes the DC more effective at priming CTLs33. Once a CTL is primed and active, it has the ability to kill.

As you can see, CTL activity is highly controlled to ensure that they react only to pathogen-associated peptides. The reason is that MHC class I can be expressed by every cell type in the body. MHC class I on a cell is like a sign advertising the health of the cell. The cell is constantly displaying samples of the proteins its making. If an active CTL recognizes one of these samples as being of viral origin, it kills that cell; eliminating a viral host.

The word humor means fluid in Latin and, therefore, humoral immune responses relate to non-cellular systems found in the bodily fluids. Weve already discussed non-cellular components of the innate immunity, however, in immunology most people are not referring to these non-cellular systems when they use the term humoral immune response. Instead, they are referring to the immune response mediated by antibodies and this is part of the adaptive immune response.

The cell behind antibody responses is the B cell. Nave B cells of the immune system produce rudimentary antibodies (see below) until other cells activate them. B cells, unlike the T cells, are not required to interact with DCs; instead B cells reside in lymphoid tissues and fish for antigens that they recognize using their B cell receptors or BCR. The BCR looks like a surface bound antibody and once it binds a molecule, the B cell engulfs it and much like the phagocytes, digests it. Just like the DC, the B cell will then present pieces of the antigen to Th cells using MHC class II molecules. Primed and activated Th cells, which recognize the presented peptides, are then able to help the B cell through a CD40-CD40 ligand interaction. The Th cell also provides cytokine signals to tell the B cell which kinds of antibodies it should make34.

This process is reminiscent of the priming process of Th cells. Signal one is the MHC class II/peptide and TCR interaction between the B cell and the T cell. Signal two is the costimulatory help provided by the T cell in the form of CD40-CD40 ligand interactions. And, signal three is the cytokine message provided by the T cell.

Helped B cells will then further differentiates into plasma cells, which can produce massive quantities of antibodies.

Antibodies, by themselves, cause very little harm. However, their strength lies in their ability to tag a molecule as harmful and block molecular functions. Antibodies enhance the functions of the innate immune system. They can bind to pathogens and particles to initiate the complement system and induce phagocytosis. They can also block/neutralize molecular interactions. Examples of this function would be an antibody that blocks the toxic effects of diphtheria toxin or antibodies the block viral binding sites to cells. Antibodies also interact directly with cells and can change their function by binding to specific antibody receptors found on the surfaces of immune cells40.

An Antibody is a small protein structure produced by B cells. It is also called an immunoglobulin (Ig). It looks like a Y and it is formed from four separate proteins. Each tip of the Y recognizes and sticks to the antigen, meaning that each antibody can bind two similar antigens. A single arm is called a Fab (Fragment, antigen binding) fragment. The base of the Y is called the Fc (Fragment constant) region and, while the Fab fragments dictate the specificity of the antigen binding, the Fc region dictates the type of antibody or isotype. The antibody isotype is dictated by the prevalent cytokines in the environment as well as additional danger signals that the B cell experienced while being helped by the Th cell41.

The first types of antibodies that a B cell can produce are IgM and IgD. The M and D refers to different classes of the Fc region. IgM is found as a pentamer, with five individual IgM antibodies bound by their Fc regions in the center forming a star. They are effective at complement activation. IgD is found as a monomer and its function is undefined. However, it has the ability to bind mast cells via an Fc receptor ( for D) and induce anti-microbial peptide secretion.

IgG antibodies are found as monomers and they are very potent at stimulating immune responses. They are capable of neutralization, inducing phagocytosis in macrophages and neutrophils via Fc receptors ( for G), activation of complement, and also the activation of NK cells (also via Fc receptors).

IgE antibodies are monomers. They are known to cause mast cell degranulation via binding of Fc receptors ( for E). They are induced during parasite infection and, unfortunately, also during allergy.

IgA is found as a dimer of two antibodies attached via their Fc regions. It is involved with mucosal defense: found in gastrointestinal system, the respiratory systems. They are particularly effective at neutralization of microbes and toxins.

Once the adaptive immune system has formed a response, the body has a long-term record of the invading pathogen in the form of long-lived plasma cells, memory T cells (not covered here) and antibodies. This is why vaccination is so important. It allows your body to create an adaptive immune response against an invader without having to truly become infected42.

When a body encounters a pathogen for the second time, its a completely different situation than the first encounter. During a second infection, T cells drawn to the inflammation site will have knowledge to help macrophages, recruit more neutrophils, and kill infected cells. Antibodies will be now present to assist complement activation, the phagocytosis of particles, and even kill microbes. The response will be quicker and more effective.

Though separating the two types of responses: innate and adaptive, helps with learning; it can also become an obstacle to seeing the immune response as a complex, dynamic system. It is important when looking at an immunological problem to consider the hosts previous history as it has so much influence on the immune response.

It is my sincere wish that this basic immunology overview helps with your understanding of the immune system. Keep in mind, that it is simplistic (skipping whole areas of immunological interest at times) and I have avoided adding too much terminology. If there are aspects that are particularly confusing, dont hesitate to mention them and I will do my best to update this document.top

1. Tauber, A. I. A. The immune self: theory or metaphor? Immunol Today 15, 134136 (1994).

2. Baldridge, M. T., King, K. Y. & Goodell, M. A. Inflammatory signals regulate hematopoietic stem cells. Trends Immunol 32, 5765 (2011).

3. Wu, L. & Liu, Y.-J. Development of Dendritic-Cell Lineages. Immunity 26, 1010 (2007).

4. Anderson, G. & Takahama, Y. Thymic epithelial cells: working class heroes for T cell development and repertoire selection. Trends Immunol 33, 256263 (2012).

5. Girard, J.-P., Moussion, C. & Frster, R. HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes. Nat Rev Immunol 12, 762773 (2012).

6. Koboziev, I., Karlsson, F. & Grisham, M. B. Gut-associated lymphoid tissue, T cell trafficking, and chronic intestinal inflammation. Annals of the New York Academy of Sciences 1207 Suppl 1, E8693 (2010).

7. Mebius, R. E. & Kraal, G. Structure and function of the spleen. Nat Rev Immunol 5, 606616 (2005).

8. Takeuchi, O. & Akira, S. Pattern Recognition Receptors and Inflammation. Cell 140, 805820 (2010).

9. Hirsiger, S., Simmen, H.-P., Werner, C. M. L., Wanner, G. A. & Rittirsch, D. Danger Signals Activating the Immune Response after Trauma. Mediators Inflamm. 2012, 110 (2012).

10. Yao, Y., Levings, M. K. & Steiner, T. S. ATP conditions intestinal epithelial cells to an inflammatory state that promotes components of dendritic cell maturation. Eur. J. Immunol. (2012).doi:10.1002/eji.201142213

11. Fujita, T., Matsushita, M. & Endo, Y. The lectin-complement pathwayits role in innate immunity and evolution. Immunol Rev 198, 185202 (2004).

12. Tarr, A. W., Urbanowicz, R. A. & Ball, J. K. The Role of Humoral Innate Immunity in Hepatitis C Virus Infection. Viruses 4, 127 (2012).

13. Le Bourhis, L. et al. Mucosal-associated invariant T cells: unconventional development and function. Trends Immunol 32, 212218 (2011).

14. Juno, J. A., Keynan, Y. & Fowke, K. R. Invariant NKT Cells: Regulation and Function during Viral Infection. PLoS Pathog 8, e1002838 (2012).

15. Sims, G. P., Rowe, D. C., Rietdijk, S. T., Herbst, R. & Coyle, A. J. HMGB1 and RAGE in Inflammation and Cancer. Annu. Rev. Immunol. 28, 367388 (2010).

16. Hardison, S. E. & Brown, G. D. C-type lectin receptors orchestrate antifungal immunity. Nat Immunol 13, 817822 (2012).

17. Weng, L. et al. Isolation and characterization of chondrolectin (Chodl), a novel C-type lectin predominantly expressed in muscle cells. Gene 308, 2129 (2003).

18. Lech, M., Avila-Ferrufino, A., Skuginna, V., Susanti, H. E. & Anders, H. J. Quantitative expression of RIG-like helicase, NOD-like receptor and inflammasome-related mRNAs in humans and mice. Int Immunol 22, 717728 (2010).

19. Rubino, S. J., Selvanantham, T., Girardin, S. E. & Philpott, D. J. Nod-like receptors in the control of intestinal inflammation. Current Opinion in Immunology 24, 398404 (2012).

20. Ireton, R. C. & Gale, M., Jr RIG-I Like Receptors in Antiviral Immunity and Therapeutic Applications. Viruses 3, 906919 (2011).

21. Artis, D. Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. Nat Rev Immunol 8, 411420 (2008).

22. Drouet, M., Dubuquoy, L., Desreumaux, P. & Bertin, B. Visceral fat and gut inflammation. Nutrition 28, 55 (2012).

23. Murray, P. J. & Wynn, T. A. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 11, 723737 (2011).

24. Nathan, C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 6, 173182 (2006).

25. Coombes, J. L. & Powrie, F. Dendritic cells in intestinal immune regulation. Nat Rev Immunol 8, 435446 (2008).

26. Sun, J. C. & Lanier, L. L. NK cell development, homeostasis and function: parallels with CD8+ T cells. Nat Rev Immunol 11, 645657 (2011).

27. Abraham, S. N. & John, A. L. S. Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol 10, 440452 (2010).

28. Godfrey, D. I., Stankovic, S. & Baxter, A. G. Raising the NKT cell family. Nat Immunol 11, 197206 (2010).

29. Kronenberg, M. & Havran, W. L. Frontline T cells: T cells and intraepithelial lymphocytes. Immunol Rev 215, 57 (2007).

30. Baumann, H. & Gauldie, J. The acute phase response. Immunol. Today 15, 7480 (1994).

31. Brogden, K. A. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nature Publishing Group 3, 238250 (2005).

32. Boehm, T. Design principles of adaptive immune systems. Nat Rev Immunol 11, 307317 (2011).

33. Behrens, G. et al. Helper T cells, dendritic cells and CTL Immunity. Immunol Cell Biol 82, 8490 (2004).

34. Cerutti, A., Puga, I. & Cols, M. New helping friends for B cells. Eur. J. Immunol. 42, 19561968 (2012).

35. Wilson, C. B., Rowell, E. & Sekimata, M. Epigenetic control of T-helper-cell differentiation. Nat Rev Immunol 9, 91105 (2009).

Go here to read the rest:
Basic Immunology | The IBD Immunologist

Clinical Immunology | Meso Scale Discovery

MSDs wide range of assay development materials and kits provide superior solutions for each stage of development in clinical and pre-clinical applications as compared to traditional methods. MSD assay sensitivity can be up to 1000-fold better than ELISA with a large linear range of 3-4 logs. MSDs electrochemiluminescence detection technology reduces background signals due to the stimulation mechanism (electricity) being decoupled from the signal (light). MSD assay formats minimize both matrix effects and free drug interference, improving both workflow and performance. MSD offers assays and reagents to enhance the performance of many clinical immunology applications, including:

Immunogenicity testing is a crucial part of biopharmaceutical development. More stringent recommendations regarding immunogenicity assay performance necessitates the development of more robust and tolerant assays. MSD assays are capable of identifying low affinity antibodies during initial screens, and have a large linear range that reduces the number of required dilutions. Assays can be built for many drug types using MSD technology, including antibodies, humanized antibodies, proteins, and peptides with reagents designed to provide a variety of flexible assay formats and facilitate rapid assay development.

Drug interference in immunogenicity assays from free drug in patient samples can cause false negatives and suppressed signal. The improved sensitivity of the MSD platform produces higher signal and lower backgrounds, leading to greater signal to background ratios, and detection of low levels of drug-anti drug antibody complexes. Improved assay sensitivity allows for larger sample dilution, further reducing drug interference.

The MSD technology platform easily facilitates the development of assays for neutralizing antibodies. These assays are a key step in the development and characterization of a biological therapeutic agent, as part of the screening process for immune responses to protein and antibody drugs. The versatility of MSD assay development reagents affords the choice of several types of neutralization assays, including a receptor binding/blocking assay format and a whole cell-based neutralization assay.

Pharmacokinetics is the study of the metabolism and action of drugs in the body, with emphasis on time course studies of adsorption, distribution, period of action, and excretion. Pharmacokinetics assays can easily be implemented on the robust MSD platform using our flexible assay development reagents.

The study of pharmacodynamics examines drug mechanisms of action, as well as their exerted biochemical and physiological effects. These effects can be generated through drug interaction with specific cellular proteins, and secreted proteins such as cytokines.

Streptavidin Gold Plates are designed to be the gold standard for assay performance, consistency, and convenience in immunogenicity testing, pharmacokinetic/pharmacodynamic studies, and assay development.

Read the original:
Clinical Immunology | Meso Scale Discovery

Immunology Market Trends, Size, Share & Global Outlook 2026

Existing market players operating in the global immunology market are focusing on constant innovations and up-gradation of their product portfolio with new and efficient product offerings for better treatment outcomes for the patients. One of the primary reasons for the growth of the global market is the increasing incidence of immunological and autoimmune diseases. Rise in awareness regarding immunological diseases in both developing and developed nations, and the higher prevalence of immunological disorders due to environmental factors, thus propelling the of the global immunology market growth. This, coupled with, increasing investments by major players in research and development activities are also boosting the growth of the market globally.

Get comprehensive study about this report by, request a free sample copy

The change in the immunology market share is also primarily driven by a greater focus towards the R&D initiatives due to recent regulatory approvals, increasing trends of patent expiry and the subsequent emergence of comparatively cheaper biosimilars. Some of the other factors which are also contributing to the growth of the market are the increase in the efficiency of the immunology drugs leading to better patient outcomes and improved quality of life.

The introduction of new and sophisticated targeted therapies such as TREMFYA by Janssen Global Services, LLC (Johnson & Johnson) and Cosentyx by Novartis AG is expected to drive the growth of the immunology market in developed as well as emerging countries, during the forecast period 2019-2026.

"Increasing adoption of monoclonal antibody (mAb), combined with the increasing prevalence of immunological diseases is driving the growth of the global market "

Increasing adoption and demand for monoclonal antibody (mAb), which is the drug class of a number of immunology drugs and has a number of associated advantages such as its status as a high specific therapy, is one of the most prominent driving factors for the growth of the global immunology industry in 2018. Increasing R&D initiatives in the monoclonal antibody segment and a large number of drugs under the segment is also driving the growth in the monoclonal antibody (mAb) segment.

The immunosuppressant segment is estimated to grow at a faster CAGR during the forecast period. This is attributed to the anticipated increase in the revenue under this drug class, with the interleukin inhibitors becoming more prominent in the immunology market trend. Currently, there is increasing adoption of the immunosuppressants in the markets in the developing nations due to its higher achievement in terms of the efficient treatment leading to improved patient outcomes, and this is expected to contribute to the growth of the market at higher CAGRs during the forecast period.

To get details on market share, speak to analyst

Based on the drug class, the global immunology market segments include monoclonal antibody (mAb), fusion proteins, immunosuppressants, polyclonal antibody (pAb), and others. Monoclonal antibody (mAb) segment is estimated to have the largest market share among the drug class types.

The targeted therapy segment accounted for a market share of 64.5% in 2018 and is expected to rise during the forecast period. Based on disease indication, the global market segments include rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, inflammatory bowel disease, prophylaxis of organ rejection, and others. Based on the distribution channel, the global immunology industry segments include hospital pharmacies, retail pharmacies, online pharmacies, and others.

"Growing Prevalence and Awareness of Autoimmune and Immunological Disorders and Increasing Adoption of Immunology Drugs Expected to Result in The Highest CAGR in the Asia Pacific"

North America generated a revenue of US$ 41,622.5 Mn in 2018 and is anticipated to account for a dominant share in the global market during the forecast period. The immunology market growth witnessed in the region is likely to be driven by the increasing adoption of advanced immunology drugs and rising prevalence of autoimmune and immunological disorders.

This is especially applicable in instances where there is a steady escalation of the symptoms and the disease progresses due to lack of efficient treatment. In developed countries, the adoption of advanced immunology drugs such as immunosuppressants is increasing along with the existing drug classes of monoclonal antibody (mAb) and polyclonal antibody (pAb) amongst others.

North America Immunology Market, 2018

To get geographical overview of this market, request a free sample copy

Europe is estimated to be the second most dominant market after North America due to substantial R&D initiatives and adoption of advanced immunology drugs. Whereas, in emerging countries such as India and China, the rise in awareness of autoimmune and immunological disorders is fueling growth in the immunology market during the forecast period.

In countries like China and India, there is an existing conflict with the high prices attached to some of the immunology drugs. However, in countries like Japan, there is increased adoption and expenditure towards advanced immunology drugs. The Latin America and Middle East & Africa market is also estimated to have future growth potential in global immunology market growth.

"AbbVie Inc., Johnson & Johnson, and Roche dominated the global immunology market in 2018 "

AbbVie Inc., emerged as the leading player with the highest market share in 2018, as the company has the patent rights to HUMIRA (adalimumab), the worlds best-selling drug. The drug accounts for the highest revenue shares in the immunology segment and is approved for a number of disease indications including rheumatoid arthritis and psoriatic arthritis. In addition, other market players are also getting product approvals such as TREMFYA by Janssen Global Services, LLC (Johnson & Johnson) and Cosentyx by Novartis AG. Other players operating in the Immunology market are Janssen Global Services, LLC (Johnson & Johnson), F. Hoffmann-La Roche Ltd, Amgen Inc., Pfizer Inc., Novartis AG, Astellas, Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., UCB SA, and ALLERGAN.

The increasing prevalence of a number of autoimmune and immunological disorders in the general population is one of the key factors boosting the global immunology market revenue. The increasing R&D initiatives in the immunology industry and the recent regulatory approvals are also positively contributing to the growth of the market. The introduction of new products in the market, along with an increasing number of patients undergoing treatment for immunological diseases globally is projected to further augment the demand for immunology drugs during the forecast period.

The report provides qualitative and quantitative insights on the immunology industry trends and detailed analysis of immunology market size and growth rate for all possible segments in the market. The market segments include drug class, disease indication, distribution channel, and geography.

To get information on various segments, share your queries with us

On the basis of the drug class, the global market segments include monoclonal antibody (mAb), fusion proteins, immunosuppressants, polyclonal antibody (pAb) and others. On the basis of disease indication, the market is categorized into rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, inflammatory bowel disease, prophylaxis of organ rejection and others. On the basis of the distribution channel, the immunology industry is categorized into hospital pharmacies, retail pharmacies, online pharmacies, and others.

Along with this, the report analysis includes market dynamics and competitive landscape. Various key insights provided in the report are the prevalence of autoimmune and immunological disorders by key countries, regulatory scenario by key regions, key industry developments, overview of regulatory scenario by key countries, an overview of current advances in R&D for immunology.

ATTRIBUTE

DETAILS

By Drug Class

By Disease Indication

By Distribution Channel

By Geography

Read the original:
Immunology Market Trends, Size, Share & Global Outlook 2026

Cuba and Thailand joint venture to manufacture cancer drugs – OnCubaNews

A Cuba and Thailand joint venture will soon start manufacturing cancer drugs, the Cuban media reported this Friday.

The enterprise is formed by the Thai pharmaceutical company Siam Bioscience (SBS) and the Cuban medicine industry and its operations will be initiated in the Association of South East Asian Nations (ASEAN), according to the official newspaper Granma, which quoted a tweet from Eduardo Ojito, director of Cubas Center for Molecular Immunology (CIM).

The publication affirms that the company emerged in 2017 to produce world-class drugs for complicated diseases, whereby the Thai SBS and the Cuban CIM agreed to jointly develop monoclonal antibodies to treat cancer and autoimmune diseases.

Songpon Deechongkit, general director of Siam Bioscience Group, to which SBS belongs, assured the Bangkok Post that by 2022 the enterprise plans to produce and sell three new drugs for cancer, kidney failure and autoimmune diseases, both in Thailand and abroad.

For his part, Agustn Lage Dvila, general director of CIM, told the publication itself that the agreement will help SBS produce other medicines when its patent expires, through the skills created in it.

Dos nuevos medicamentos para el cncer dan buenos resultados

The Thai pharmaceutical giant, according to the source, has as its main objective to reduce the costs of medicines with respect to imported products and seeks to reduce dependence on active ingredients and foreign components.

SBS has previously developed medications such as erythropoietin for patients with chronic renal failure and filgrastim for cancer patients receiving chemotherapy. Its operations have crossed Thailands borders to include ASEAN countries.

Established in 2009, Siam Bioscience has the mission of supporting and enhancing the countrys medical system and improving Thais quality of life, an objective that will now be extended to other ASEAN countries, which also include Indonesia, Malaysia Singapore and the Philippines.

See the original post:
Cuba and Thailand joint venture to manufacture cancer drugs - OnCubaNews

THE REAL POLLEN COUNT: Grass season spreading to the coast – Health24

Amid the highest recorded pollen counts in history, Health24 will be bringing you exclusive pollen count updates courtesy of the UCT Lung Institute's Allergy and Immunology Unit.

Here are the major city updates for 20 February:

Cape Town (Western Cape)

Low grass counts were detected during this sampling week. Tree levels were low and included white stinkwood and pine. Weed levels were also low and the types identified were the daisy family, goosefoot and Erica. Moulds were low.

Count: 2 (very low) [Last week: 0 (very low)]

Johannesburg (Gauteng)

Grass counts were moderate throughout this sampling week. Very few tree pollens were in the air, with only a few grains of cypress and eucalyptus. Weeds were also low, with predominantly daisy detectable. Fungal spores were low.

Count: 18 (moderate) [Last week: 11 (moderate)]

Pretoria (Gauteng)

Overall counts were in the high range with grass pollen high to very high on most days of the sampling week. Tree pollen was minimal with only cypress, mulberry and eucalyptus detected.

Weed pollen, in the form of daisy was only detectable on two days. Fungal spores at the upper end of the low range, with aspergillosis and Cladosporium dominant.

Count: 35 (high)

Kimberley (Northern Cape)

Count: 12 (moderate) [Last week: 33 (high)]

Durban (KZN)

Grass levels were high at this sampling site. Tree loads increased, and were dominated by birch, with eucalyptus and white stinkwood also recorded. Weed levels were low, including ragweed.

Count: 45 (high) [Last week: 24 (high)]

Port Elizabeth

Grass levels were low. Tree were low and included Casuarina, Morella (waxberry)and yellowwood.

Weeds were low and the types detected were protea, the daisy family and Caryophyllaceae (the carnation family). Moulds were low, but increased after rain.

Count: 5 (low) [Last week: 1 (very low)]

Bloemfontein

Count: 97 (very high) [Last week: 114 (very high)]

See the full report HERE.

Reference ranges:

Overall, Trees, Grasses and Weeds all use the same values (grains per cubic metres of air).

Overall count is the daily average of pollen grains per cubic metres of air (trees plus grasses plus weeds)

In partnership with the UCT Lung Institute's Allergy and Immunology Unit.

As the pollen problem worsens, precise and expanded monitoring becomes even more essential. And here's how you can help.

Image: iStock

Read more:
THE REAL POLLEN COUNT: Grass season spreading to the coast - Health24